In conclusion, our study indicated that the use of BL-BLIs and nitroimidazoles within 12 months prior to the ADA test might increase the risk of ADA formation during anti-TNF therapy in Chinese IBD patients, while the treatment with fluoroquinolones could probably reduce such risk. The gene discussed is ADA; the disease is inflammatory bowel disease.